Newstral
Paul Matteis
- BLululemon Soars, Cisco Drops as Stocks Slip Ahead of ECB2 min readbarrons.com
- BAthira Pharma Falls 40% Amid Questions About CEO's PhD Research2 min readbarrons.com
- BThe $56,000 Price of Biogen's Alzheimer's Drug Could Backfire4 minbarrons.com
- BAcadia Shares Plummet After FDA Finds Flaws in Drug Applicationbarrons.com
- BVertex Slides a Surprise Halt to a Promising Drug Trialbarrons.com
- MGW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish viewmarketwatch.com
- MInvestors flock to psychiatric treatments after FDA approves new schizophrenia drugmarketwatch.com
- BAlexion CFO Is Unexpectedly Leavingbarrons.com
- MCannabis stocks weighed down by broader market, but Aleafia and GW Pharma shinemarketwatch.com
- MGW Pharma shares soar 9% premarket as Oppenheimer upgrades to outperformmarketwatch.com
- MZogenix shares down 23% after FDA refuses to review company’s marketing application for seizure drugmarketwatch.com
- MGW Pharma stock rallies in declining cannabis sector after strong Epidiolex launchmarketwatch.com
- MGW Pharmaceuticals stock soars after earnings report prompts upbeat analyst callsmarketwatch.com
- MAlkermes stock halted as FDA committee considers depression drugmarketwatch.com
- MMarijuana stocks to watch: GW Pharma is a drugmaker that grows its own cannabis plantsmarketwatch.com
- MAlnylam shares drop 1.8% on new FDA approval strategy for rare disease drugmarketwatch.com
- MGW Pharma stock jumps to record after DEA stance on its CBD drug, cannabis sector lagsmarketwatch.com
- MPfizer stock drops 2% as positive rare-disease drug results won’t stop competitorsmarketwatch.com
- MGW Pharma's cannabis-derived drug to be reviewed by FDAmarketwatch.com
- MAcorda stock drops 40% on patient deaths related to its Parkinson’s drugmarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.